Anlotinib

Generic Name: Anlotinib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₂FN_₃O_₃

CAS Number: 1058156-90-3

Unique Ingredient Identifier: GKF8S4C432

Background: Anlotinib has been investigated for the treatment of Non-small Cell Lung Cancer and Metastatic Colorectal Cancer.

Indication: 用于治疗非小细胞肺癌、结直肠癌、肾癌、软组织肉瘤、甲状腺癌、胃癌等。

用于无法手术的局部晚期或转移性甲状腺髓样癌患者的治疗。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer

Phase 2

Recruiting

Conditions: Pancreatic Adenocarcinoma Metastatic

Interventions: Drug: Nab paclitaxel
Drug: Penpulimab
Drug: Gemcitabine
Drug: Anlotinib

First Posted Date: 2023-09-25

Last Posted Date: 2023-09-25

Lead Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Target Recruit Count: 177

Registration Number: NCT06051851

Locations: 🇨🇳
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China

A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody

Phase 3

Not yet recruiting

Conditions: Lung Cancer
Pianzumab
TKI Resistance
EGFR Sensitive Mutation
Anlotinib

First Posted Date: 2023-09-21

Last Posted Date: 2023-09-21

Lead Sponsor: Degan Lu

Target Recruit Count: 52

Registration Number: NCT06048315

A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC

Phase 2

Recruiting

Conditions: Extensive Stage Small Cell Lung Cancer

Interventions: Drug: Tislelizumab
Drug: Anlotinib

First Posted Date: 2023-06-09

Last Posted Date: 2023-06-09

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 21

Registration Number: NCT05896059

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Anlotinib Capsules in the Treatment for IPF/PF-ILDs

Phase 2

Recruiting

Conditions: Interstitial Lung Diseases

Interventions: Drug: Placebo
Drug: Anlotinib

First Posted Date: 2023-04-25

Last Posted Date: 2024-07-17

Lead Sponsor: First Affiliated Hospital of Wenzhou Medical University

Target Recruit Count: 30

Registration Number: NCT05828953

Locations: 🇨🇳
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer

Phase 2

Recruiting

Conditions: Cervical Cancer

Interventions: Drug: Cadonilimab
Drug: Anlotinib
Drug: Granulocyte-Macrophage Colony-Stimulating Factor

First Posted Date: 2023-04-18

Last Posted Date: 2024-04-19

Lead Sponsor: Zhongnan Hospital

Target Recruit Count: 35

Registration Number: NCT05817214

Locations: 🇨🇳
Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China

Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 1

Active, not recruiting

Conditions: NSCLC Stage IV
NSCLC Stage IIIB
NSCLC Stage IIIC

Interventions: Drug: Cadonilimab
Drug: Anlotinib
Drug: Docetaxel

First Posted Date: 2023-04-18

Last Posted Date: 2024-06-17

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 50

Registration Number: NCT05816499

Locations: 🇨🇳
lejie Cao, Hefei, Anhui, China
🇨🇳
Jing Wang, Qingdao, Shandong, China
🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

and more 2 locations

PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer

Phase 2

Recruiting

Conditions: Thyroid Cancer

Interventions: Drug: Tislelizumab
Drug: Anlotinib
Radiation: Radiotherapy

First Posted Date: 2022-12-21

Last Posted Date: 2022-12-21

Lead Sponsor: West China Hospital

Target Recruit Count: 20

Registration Number: NCT05659186

Locations: 🇨🇳
Xingchen Peng, Chengdu, Sichuan, China

Anlotinib and Radiotherapy in Resectable Soft Tissue Sarcoma

Phase 2

Recruiting

Conditions: Soft Tissue Sarcoma
Anlotinib
High Risk of Recurrence
Radiotherapy

Interventions: Drug: Anlotinib
Radiation: Radiotherapy
Procedure: Surgery

First Posted Date: 2022-11-02

Last Posted Date: 2022-11-02

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 41

Registration Number: NCT05602415

Locations: 🇨🇳
Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer

Phase 2

Recruiting

Conditions: Breast Cancer Stage II

Interventions: Drug: Anlotinib

First Posted Date: 2022-09-28

Last Posted Date: 2022-09-28

Lead Sponsor: Xijing Hospital

Target Recruit Count: 30

Registration Number: NCT05558722

Locations: 🇨🇳
Xijing Hospital Affiliated to Air Force Military Medical University, Xi'an, Shannxi Province, China

A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer.

Phase 2

Completed

Conditions: Pancreatic Neoplasms

Interventions: Drug: Penpulimab
Drug: Anlotinib
Drug: Nab paclitaxel
Drug: Gemcitabine

First Posted Date: 2022-08-09

Last Posted Date: 2024-05-09

Lead Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Target Recruit Count: 66

Registration Number: NCT05493995

Locations: 🇨🇳
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy